ARCHIVES

Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.

This article is from The Cancer Letter archive.

Vol. 31 No. 37 | October 14, 2005

Download PDF Visit The Full Archive

Related Articles

Investigators Unlocking Drug Resistance Secrets, NCI Study, Bristol-Myers Meeting Reports Show

November 28, 1986

Cedars-Sinai Develops Criteria For FDG-PET In Breast Cancer

August 25, 2006

In Brief: FDA’s Tabor To Head Biological Carcinogenesis in DCE; Steve Larson to Leave NIH for Memorial

April 29, 1988

NCI Cooperative Group, Cancer Center Trials Listed

November 28, 2008

GM Sends STAR Information To Its Female Employees.

February 23, 2001

HEW Approves New Cancer Clinical Education Grants, Without Trainee Stipends ; $4 Million Available In ’75

April 26, 1974